COMPASS Pathways plc Q2 FY2026 earnings call

• Clinical & Regulatory Progress: The company achieved statistically significant positive Phase 3 primary endpoint results for Comp360, with demonstrated efficacy durability through 6 months, a well-tolerated safety profile, rapid onset of symptom improvement as early as 1 day, and reproducible efficacy in the hard-to-treat TRD patient population. A rolling New Drug Application (NDA) submission to the FDA is underway, with some modules already submitted and under review. Full 52-week safety data from both Phase 3 trials will ultimately be provided to the FDA, with 26-week blinded data currently integrated into the submission dossier. The 300-patient Phase 3 trial for PTSD is underway, with a cap of no more than 15% of patients from VA/military backgrounds aligned with population prevalence. The company has restarted its Investigator Activated Studies (IAS) program across additional indications including OCD, after a multi-year pause, and has supplied study drug for numerous IAS across a range of potential indications. The company holds $433 million in cash on hand as of June 30, sufficient to fund operations through launch and into 2028.
• Commercial Readiness: The full commercial leadership team has been hired, with leaders from major pharmaceutical companies who collectively have led over 70 product launches, and the company is actively recruiting its field sales force. Total strategic collaboration partnerships now stand at 8, with recent additions of Radial and Osmind, focused on optimizing site and patient experience at launch. There are over 8,000 existing interventional psychiatry treatment sites in the U.S. (growing ~500 sites per quarter) already equipped to deliver Comp360, with existing capacity, trained staff, and experience administering multi-hour monitoring treatments like Spravato. Pre-launch market research shows ~90% of interventional psychiatrists report they will prescribe Comp360 within the first year of approval, the highest willingness-to-prescribe rate the commercial leadership team has ever observed. The company has already funded third-party training for sites, with over 1,000 clinicians already trained on general psychedelic administration protocols. Medical Science Liaisons have been active in the field for 2.5 years providing clinician education. The company plans to collect real-world evidence post-launch to better understand Comp360 performance across patient populations and identify future indication opportunities.

This earning call focuses entirely on clinical, regulatory, and commercial progress for Compass Pathways' lead product candidate Comp360 (psilocybin for treatment-resistant depression, TRD). No financial segment performance data for product segments was reported in this call.

• NDA submission completion is still expected in Q4 2026, with the potential for accelerated approval following final submission
• Launch is still anticipated to occur in H1 2027; timing remains fluid due to DEA and state rescheduling requirements, but the company expects DEA to complete rescheduling within its standard 90-day window and the April 2026 executive order may enable faster timelines
• Near-term company focus is maintained exclusively on Comp360 NDA submission, approval preparation, and TRD launch, with expansion to new indications following successful launch and approval
• Post-approval, the company expects to leverage the interval between FDA approval and DEA/state rescheduling to complete site training and REMS certification preparation

• Launch timing remains uncertain due to required DEA and state rescheduling, even after FDA approval
• Reimbursement and formulary access negotiations will take time after approval, which may impact initial launch adoption
• Comp360 is the first psychedelic therapy to undergo FDA approval, so regulatory review and REMS finalization processes are untested for this new product class
• Future competition from shorter-duration psychedelic candidates may impact market share, though management does not see treatment duration as a limiting factor for Comp360 adoption given existing site capacity and economic dynamics

Q: How do the recently finalized FDA psychedelic guidelines, specifically the 12-month blinded durability requirement, impact Comp360's ongoing regulatory review?

A: The FDA guidelines were finalized after Comp360's Phase 3 trial design was agreed upon with the FDA. Management does not expect the new guidelines to impact the ongoing approval process for Comp360, as the existing trial design already aligns with FDA recommendations for Phase 3 study design. The guidelines will only be considered for future development programs.

Q: What are the key reimbursement challenges expected for launch, and how is the company preparing?

A: The company's market access team has been engaging with payers for some time, and has received very positive feedback, as payers recognize the large unmet need and economic burden of TRD, where few effective treatments exist. A dedicated field reimbursement team will be fully deployed at launch to support sites with coding and reimbursement processes. The company is still integrating recent Phase 3 data into its value proposition, and will finalize rebate and formulary negotiation strategies closer to launch.

Q: What is the company's strategic plan for future development after the TRD launch to maintain market leadership?

A: PTSD is the clear next strategic priority, with the Phase 3 trial already underway. After TRD approval and launch, the company will prioritize additional indications for Comp360, with alcohol use disorder and OCD identified as high-potential areas. Ex-U.S. commercialization will likely be done via partnerships, and the company expects to evaluate additional psychedelic assets as a first-to-market leader in the space.

Q: What is the company's site targeting strategy for initial launch training?

A: The company's field team will target all ~8,000 existing U.S. interventional psychiatry sites to provide education and training for any site willing to prescribe Comp360. It will also engage referring physicians with high volumes of TRD patients. Comp360's infrequent dosing profile expands the eligible patient radius for sites, making even suburban and less central sites viable for access.